Browse Drug Recalls
1,317 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 1,317 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 1,317 FDA drug recalls in IL.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Oct 24, 2014 | Meropenem I.V. 1 g is supplied in 30 mL injection vials, RX only. Manufactur... | Defective Container: Glass vials may crack due to low (thin) out of specification vial wall thick... | Class II | Hospira Inc. |
| Oct 20, 2014 | Z-COTE HP 1 TRANSPARENT ZINC OXIDE, Zinc Oxide (and) Triethoxycaprylylsilane,... | cGMP Deviation; The incorrect amount of a raw material was added during the manufacture of two lo... | Class III | Nanophase Technologies Corporation |
| Oct 16, 2014 | 1% LIDOCAINE HCl Injection, USP, 10 mg/mL, 30 mL Single-dose, Preservative-Fr... | Presence of particulate matter: A returned customer sample was evaluated and found to have human ... | Class I | Hospira Inc. |
| Oct 14, 2014 | Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1... | Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container... | Class II | Hospira Inc. |
| Oct 14, 2014 | Normosol-R pH 7.4 Multiple Electrolytes Injection Type 1, USP, 1000 mL contai... | Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container... | Class II | Hospira Inc. |
| Oct 14, 2014 | Normosol-R Multiple Electrolytes Injection Type 1, USP, 1000 mL container, R... | Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container... | Class II | Hospira Inc. |
| Oct 14, 2014 | Lactated Ringer's and 5% Dextrose Injection, USP; 1000 mL container, Rx Only,... | Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container... | Class II | Hospira Inc. |
| Oct 14, 2014 | Lactated Ringer's Injection, USP, 1000 mL container, Rx Only, Manufactured by... | Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container... | Class II | Hospira Inc. |
| Oct 14, 2014 | 5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx O... | Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container... | Class II | Hospira Inc. |
| Oct 14, 2014 | 5% Dextrose Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospi... | Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container... | Class II | Hospira Inc. |
| Oct 14, 2014 | 0.9% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured... | Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container... | Class II | Hospira Inc. |
| Oct 14, 2014 | Sterile Water for Injection, USP, 1000 mL container, Rx Only, Manufactured by... | Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container... | Class II | Hospira Inc. |
| Oct 14, 2014 | 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufacture... | Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container... | Class II | Hospira Inc. |
| Oct 14, 2014 | 5% Dextrose and 0.9% Sodium Chloride Injection, USP, 1000 mL container, Rx O... | Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container... | Class II | Hospira Inc. |
| Oct 6, 2014 | Vancomycin Hydrochloride for Injection, USP, 500 mg Sterile Powder per Flipto... | Temperature Abuse: Products experienced uncontrolled temperature excursions during transit. | Class II | Hospira Inc. |
| Oct 6, 2014 | Vancomycin Hydrochloride for Injection, USP, 1 g Sterile Powder per Fliptop V... | Temperature Abuse: Products experienced uncontrolled temperature excursions during transit. | Class II | Hospira Inc. |
| Oct 6, 2014 | Ketorolac Tromethamine Inj., USP, 60 mg (30 mg/mL), 2 mL Single-dose Fliptop ... | Temperature Abuse: Products experienced uncontrolled temperature excursions during transit. | Class II | Hospira Inc. |
| Oct 6, 2014 | Propofol Injectable Emulsion, 1%, 200 mg/20 mL (10 mg/mL), 20 mL Single patie... | Temperature Abuse: Products experienced uncontrolled temperature excursions during transit. | Class I | Hospira Inc. |
| Oct 3, 2014 | Ketorolac Tromethamine INJECTION, USP, 30 mg per mL, a) 1 mL vial (NDC 25021-... | Incorrect or Missing Lot and/or Exp Date: Ketorolac Tromethamine Injection, is being recalled as... | Class II | Sagent Pharmaceuticals Inc |
| Oct 1, 2014 | Hydromorphone Hydrochloride Injection, USP, 10 mg/mL, Rx only, packaged in a)... | Lack Of Assurance Of Sterility: Confirmed customer complaints of glass product container vials th... | Class II | Hospira Inc. |
| Sep 29, 2014 | DOPamine Hydrochloride and 5% Dextrose INJ, USP, 200 mg per 250 mL, Rx Only, ... | Lack of Assurance of Sterility: A small cut in the solution bag may have been introduced during t... | Class II | Baxter Healthcare Corp. |
| Sep 15, 2014 | CREON (pancrelipase) Delayed-Release Capsules, Lipase 24,000 USP Units, 250 C... | Presence of Foreign Tablets/Capsules; Presence of co-mingled LipaCreon 13000. | Class II | AbbVie Inc |
| Sep 15, 2014 | Tarceva (erlotinib) Tablets, 150 mg, 30 count bottle, Rx only, Manufactured ... | Failed Dissolution Specifications: The product did not meet the acceptance criteria for the disso... | Class II | Astellas Pharma US Inc |
| Sep 11, 2014 | HEPARIN SODIUM, 1000 USP Heparin Units/500 mL (2 USP Heparin Units/mL), in 0.... | Presence of Particulate Matter: A particulate, confirmed as human hair, was found sealed between ... | Class I | Hospira Inc. |
| Sep 9, 2014 | Buprenorphine Hydrochloride Injection, CIII, 0.3 mg base/mL ,1 mL, 10 Carpuj... | Failed Impurities/Degradation Specification: Out of Specification results for pseudobuprenorphine... | Class II | Hospira Inc. |
| Sep 8, 2014 | Potassium Chloride Injection, 10 mEq per 100 mL, Highly Concentrated (100 mEq... | Correct Labeled Product Mispack: Shipping cartons labeled as containing Potassium Chloride inject... | Class II | Baxter Healthcare Corp |
| Sep 4, 2014 | Bupivacaine HCl Inj., USP, 0.5% (5 mg/mL), 30 mL Single-dose Preservative-Fre... | Presence of Particulate Matter: A confirmed customer complaint reported the presence of a brown,... | Class II | Hospira Inc. |
| Aug 27, 2014 | Dihydroergotamine mesylate 1 mg/mL injection solution packaged in an amber gl... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Nalbuphine 10 mg/mL injection solution packaged in an amber glass injectable ... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Fentanyl/bupivacaine 3000 mcg/30 mg/mL injectable packaged in 30 mL or 60 mL ... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Tri-mix, 15 mg/0.5 mg/10 mcg/mL (papaverine, phentolamine mesylate, alprostad... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Bacteriostatic water for injection packaged in an amber glass injectable vial... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Prednisolone acetate 50 mg/mL injectable packaged in an amber glass injectabl... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Tri-mix T106, 30 mg/1 mg/25 mcg/mL (papaverine, phentolamine mesylate, alpros... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Bupivacaine hydrochloride 0.25% injectable packaged in an amber glass injecta... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Triamcinolone acetonide (PF) 40 mg/mL injection suspension packaged in an amb... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Sodium tetradecyl sulfate 2% (PF) injectable packaged in an amber glass injec... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Hydromorphone/bupivacaine (PF) 0.5 mg/0.2 mg/mL injectable packaged in 30 mL ... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Tri-mix T25, 4.413 mg/0.145 mg/1.475 mcg/mL (papaverine, phentolamine mesylat... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Calcium chloride (PF) 100 mg/mL injectable packaged in an amber glass injecta... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Cyclosporine/corn oil stock vehicle oil packaged in an amber glass injectable... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Histamine 2.75 mg/mL injectable packaged in an amber glass injectable vial, M... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Cefazolin forte 25 mg/mL opthalmic solution packaged in an opaque squeeze bot... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Chlorhexidine gluconate 0.02% opthalmic solution packaged in an opaque squeez... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Pilocarpine (PF) 0.25% opthalmic solution packaged in an opaque squeeze bottl... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Tri-mix, 30 mg/2 mg/20 mcg/mL (papaverine, phentolamine mesylate, alprostadil... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Tri-mix, 12 mg/1 mg/9 mcg/mL (papaverine, phentolamine mesylate, alprostadil)... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Tri-mix ST9-A, 30 mg/2 mg/80 mcg/mL (papaverine, phentolamine mesylate, alpro... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | Hydroxocobalamin 5 mg/mL injectable packaged in an amber glass injectable via... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
| Aug 27, 2014 | PGE 1, 40 mcg/mL injectable packaged in a clear glass injectable vial, Martin... | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of ... | Class II | Martin Avenue Pharmacy, Inc. |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.